Cointime

Metavention

company

About

Metavention develops medical devices to help with interventional therapies for high blood pressure and other metabolic diseases.

Highlights

Total Funding Amount
$65M
Funding Rounds
1
Investors
5
Employee Profiles
5

Details

Last Funding Type
Series C
Last Funding Money Raised
$65M
Industries
Biotechnology,Diabetes,Health Care
Founded date
Jan 1, 2012
Number Of Employee
1 - 10
Operating Status
Active
Legal Name
Metavention, Inc.

Metavention develops new treatment that is intended to permanently disrupt the overactive nerves that cause high blood pressure and other metabolic diseases. They offer a renal denervation procedure that delivers radio frequency energy to targeted overactive sympathetic nerves using their IRF denervation system.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$65M
Metavention has raised a total of $65M in funding over 2 rounds. Their latest funding was raised on Jan 8, 2018 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 8, 2018 Series C $65M 5 New Enterprise Associates — Detail

Investors

Number of Lead Investors
Number of Investors
1
5
Metavention is funded by 5 investors. New Enterprise Associates and RK Mellon are the most recent investors.
Investor Name Lead Investor Funding Round
New Enterprise Associates Yes Series C
RK Mellon — Series C
Horowitz Group — Series C
Sanderling Ventures — Series C
Versant Ventures — Series C

Employee Profiles

Number of Employee Profiles
5
Metavention has 5 current employee profiles, including Board member Kevin Hykes
Kevin Hykes
Board member
Kirk G. Nielsen
Board member
Todd Berg
Executive
Scott Vafai
Executive
Kavitha Ganesan
Executive
Cointime
Content
Company